In 2010, both Chinese medicine import and export have grown into private enterprises.

Business News Agency February 22th With the waning of the financial crisis, the global market’s demand for Chinese pharmaceutical products is picking up, China’s pharmaceutical foreign trade has accelerated its pace of growth, and the increasingly popular international concept of green has provided a rare development for Chinese medicine exports. Opportunity. According to the latest customs statistics, in 2010, China’s imports and exports of Chinese medicines were US$ 2.632 billion, an increase of 22.74% year-on-year. Among them, the export value of 1.944 billion US dollars, an increase of 22.78%; import value of 688 million US dollars, an increase of 22.61%.

Imports and exports of Chinese medicines General overview Imports and exports of various commodities Imports and exports of pharmaceutical products The deficit of Chinese herbal medicines and health products increased In 2010, the export volume of plant extracts was US$815 million, a year-on-year increase of 17.62%, accounting for 41.92% of the total export volume of Chinese medicines. The extracts were still Chinese medicines. The main export of goods; the import volume of extracts was 130 million U.S. dollars, an increase of 7.16% year-on-year, accounting for 18.95% of the total imports of Chinese medicines. The export volume of Chinese herbal medicine decoction pieces was US$776 million, an increase of 28.07% over the same period of the previous year, accounting for 39.89% of the total exports of Chinese herbal medicines. The export volume of Chinese patent medicines was 193 million U.S. dollars, an increase of 18.05% year-on-year; the import value was 218 million U.S. dollars, a year-on-year increase of 23.71%. The Chinese patent medicine trade has shown a deficit since 2008, and it continued into 2010, and the deficit has increased. In addition to 2006, trade in health products has been in a deficit from 2003 to 2010. In 2010, the export volume was US$161 million, a year-on-year increase of 32.27%; the import volume was US$203 million, an increase of 30.33% over the same period last year. Although the import and export of health products in the trade of traditional Chinese medicines increased by the largest year-on-year, the deficit amounted to US$42 million, a record high.

Exports continue to focus on traditional markets ASEAN has become a new bright spot Japan, Hong Kong, the United States, and South Korea are still the main export markets for traditional Chinese medicines. In 2010, exports increased by more than 10%. The export volume to these four markets accounted for 48.71% of China's total exports of Chinese medicines.

The EU is one of the world's largest vegetable medicine markets and one of the major destinations for Chinese proprietary Chinese medicine exports. The Directive on Traditional Plant Drug Registration Procedures promulgated by the European Union on March 31, 2004 stipulated that all plant drugs sold on the EU market must be registered before April 30th, 2011 in accordance with the new regulations and obtain marketing approval. Otherwise, Chinese medicines currently circulating in the EU market in the form of foods, health products, etc. will be prohibited from selling. In 2010, the export value of China's Chinese patent medicines to the European Union was US$12,523,800, a year-on-year increase of only 15%, far lower than the average annual increase of 25% in the exports of Chinese patent medicines to the EU in previous years. Although faced with the problems of high registration fees, small market size, and slower growth of exports to the EU, some Chinese medicine companies have not lost confidence in the EU market and have started registration. The China Medicare Association is also urging “Foreign Trade Development Promotion Funds”. "Support the project.

In January 2010, the China-ASEAN Free Trade Area Agreement was formally implemented. Tariffs on trade in traditional Chinese medicines between China and ASEAN countries have been greatly reduced, and customs clearance has become more convenient. Affected by this, in 2010 China's import and export volume of ASEAN's traditional Chinese medicines increased by 28.05% year-on-year to US$422 million, which is higher than the annual average increase of imports and exports of Chinese medicines by 6 percentage points. Among them, exports were 337 million U.S. dollars, an increase of 26.97 percent year-on-year; imports were 85 million U.S. dollars, an increase of 32.55% year-on-year, and both import and export saw rapid growth. Malaysia, Vietnam and Singapore are the major markets for the export of Chinese medicines, of which Malaysia mainly imports plant extracts from China, and Vietnam mainly imports pieces of Chinese herbal medicines. Singapore has a relatively mature Chinese patent medicine registration regulation. The Chinese patent medicine market is relatively mature and has become one of the main destination countries for China's proprietary Chinese medicine exports to ASEAN.

Export enterprises have a diversified structure of private enterprises as the main force In 2010, a total of 3,263 export enterprises of traditional Chinese medicine products, 332 more than in 2009, private enterprises became the main force of exports, the export value accounted for as much as 48.02%; "three foreign-funded" enterprises export amount Accounting for 29.12%; state-owned enterprises accounted for only 22.7% of exports. It is worth noting that private enterprises account for more than 90% of private enterprises.

In 2010, there were 1,591 enterprises engaged in the import of traditional Chinese medicine products, of which “three-funded” enterprises imported USD 302 million, accounting for 43.84%; private enterprises imported USD 300 million, accounting for 43.64%; state-owned enterprises imported only 8558 Ten million US dollars, accounting for 12.44%.

Chinese medicine exports of various characteristics of Chinese herbal medicines Pieces:

Price increases have been throughout the year since the beginning of 2010, and Chinese herbal medicine prices have started to increase significantly. The prices of 84% of the 537 commonly used Chinese herbal medicines on the market have risen, generally between 5% and 180%. Among them, Taizishen has the most significant price increase, which has increased by 353% throughout the year. The price of Codonopsis has also risen by 162%; March 7 has risen by 68%; other Chinese medicine varieties such as Cordyceps, Chinese angelica, etc. have also seen different levels of price increases.

The increase in domestic prices of Chinese herbal medicines led to an increase in the export value of Chinese herbal medicines. In 2010, the export value was 509 million US dollars, a year-on-year increase of 25.9%. The average export price increased by 13.4% year-on-year, and prices of some medicinal herbs continued to rise. For example, Fritillaria, the price increased by 454% year-on-year; Tianqi, the price increased by 245% year-on-year; Cordyceps sinensis, the price increased by 142% year-on-year; Coptis chinensis, the price increased by 61% year-on-year; The price increased by 51% year-on-year. However, the volume of these Chinese herbal medicines with skyrocketing prices has generally declined by 30% to 40%.

The sharp increase in prices of Chinese herbal medicines is mainly caused by three factors: First, in 2010, the southwest region of China experienced a series of natural disasters such as drought, floods, and mudslides, which led to the reduction or even the loss of Chinese herbal medicines in the region, and the Chinese herbal medicines in the southwest region. The output and species accounted for more than 50% of the national Chinese herbal medicine market, which directly led to a decrease in the supply of Chinese herbal medicines; second, the market demand for Chinese herbal medicines continued to expand. The raw materials of health care products were mostly Chinese herbal medicines, and more and more people began to take Chinese medicines. Health products to regulate the body, prevent diseases, making China's health care products market continues to expand, the price of Chinese herbal medicines rose, China's health products market has ranked second in the world; Third, hot money speculation to promote the irrational growth of Chinese herbal medicine prices, in Under the macro-control of the property market, the withdrawal of capital from the property market was no less than 300 billion yuan, and part of the funds flowed into the Chinese herbal medicine market, which caused a hoarding and led directly to the rise in prices of Chinese herbal medicines.

Plant extracts:

Export continued to rise In 2010, the export volume of plant extracts was US$815 million, a year-on-year increase of 17.62%, which continued to maintain a growth trend, and it has occupied the top spot in the export of traditional Chinese medicine for many years. Monthly exports of plant extracts were basically stable, and the export value remained at around US$65 million, indicating that the demand for plant extracts in the international market remained strong.

From the perspective of export product structure, the largest increase in export value is natural pigment products. In terms of single species, the export value of stevia extracts increased significantly. Among the top ten export companies, three companies mainly export stevia extracts. In addition, the pigments used in foods, such as capsanthin and lutein, have also become hotspots for export growth in recent years.

The plant extract industry has a certain clustering effect, and the plant extracts industries in each province have their own characteristics. Shandong mainly produces plant extracts for food additives, while Zhejiang and Shanghai use plant extracts for medicinal and health products. From the statistical data, in 2010, the export of food additives and flavors and plant extracts of the provinces, exports have increased substantially, such as Shandong and Jiangxi, Stevia extract export growth is greater, Yunnan exports of flavor and fragrance also More obvious. Exports to provinces and cities for the export of pharmaceutical and health products used plants, exports have declined slightly, such as Zhejiang and Beijing.

In 2010, the main export markets of China's plant extracts were still Japan and the United States, and the export value exceeded US$100 million. However, the export growth rate has been in a weak state, both below 10%. The most striking is the EU market. EU countries, mainly Germany, France, and the United Kingdom, imported more than 60% of their plant extracts in 2010. Most of the products are used to produce botanicals and food supplements. The production of health products, foods, beverages and natural health products in EU countries all require extracts of natural plants, and they are used in large amounts, which provides ample space for the export of plant extracts in China. In particular, in the face of the EU Herb Registration Directive within a limited period of time, it is difficult for most Chinese companies to complete the registration in the form of pharmaceuticals in a short period of time. From this perspective, exporting Chinese medicine extracts to the EU is also a way out. In 2010, China's export of plant extracts to the EU was US$182 million, an increase of 49.15% year-on-year, which was much higher than the average increase in the export of plant extracts in China. However, it should also be noted that in recent years, international requirements for heavy metals and pesticide residues have become more stringent. The production technology and product quality of Chinese herbal extracts need to be continuously improved, and the product structure needs to be further optimized.

Chinese patent medicine:

Increase in trade deficit In 2010, the import and export of proprietary Chinese medicines reached 411 million U.S. dollars, a year-on-year increase of 21%. Among them, exports were 193 million U.S. dollars, imports were 218 million U.S. dollars, and the deficit increased.

In 2010, China's proprietary Chinese medicines were exported to 143 countries and regions, among which Singapore, Malaysia, and Hong Kong were the countries with larger increases in exports; Benin, Russia, and South Korea saw the largest declines in exports. The main sources of imports of Chinese patent medicines in 2010 were Germany, Hong Kong and Japan, and the increase from Germany and Japan reached 52.44% and 52.86%, respectively.

China's Hong Kong, Japan, and the United States are still the main export markets of Chinese proprietary Chinese medicines, accounting for about 57% of China's proprietary Chinese medicine exports. China's Hong Kong area is the most concentrated area of ​​Chinese patent medicine exports. The export ratio is as high as 41.7%, and the amount is 80.49 million US dollars, an increase of about 19.53% over the same period of last year. On the one hand, it is because Hong Kong has a strong consumer demand for proprietary Chinese medicines. On the other hand, because some Hong Kong merchants have branches in the United States and Europe, Hong Kong has become a transit point for Chinese patent medicines for global exports.

Health products:

The increase in imports and exports was significant, and the deficit was still US$161 million in China’s exports of health products in 2010, an increase of 32.27% year-on-year; imports were US$203 million, a year-on-year increase of 30.33%. There are 98 export countries and regions, of which the larger increase in exports is the United States, Vietnam, and Indonesia; the larger decline in exports is Saudi Arabia and Hong Kong.

The United States and Japan are the major countries in the export of health products in China, accounting for more than 60% of the exports of health products. In 2010, China’s health products continued to increase in exports to traditional markets such as North America and the European Union. However, in recent years, the growth of China's exports of health products to Japan has slowed down. This is mainly due to the fact that Japan has stricter requirements for certain health foods, which allows companies to invest more in research and production, but the benefits are not significant. According to statistics, the development of the entire health food market in Japan is not optimistic. According to statistics, the total market volume of Japanese healthy foods has gradually declined since 2005, and it is expected that before 2012, the market will show a slow development trend, and the entire market will recover until 2013. In 2010, China’s exports of Japanese health products were US$30.5 million, a year-on-year increase of only 2.59%. Due to the sluggish consumption of health products in Japan and the reduction of orders, in 2010 China's exports of fresh royal jelly and fresh royal jelly powder to Japan fell to a certain extent.

In 2010, the export of health products in China was dominated by fish oil, inositol, seaweed and royal jelly products. The major export provinces and cities were Zhejiang, Guangdong, Shandong, and Jiangsu, among which Shandong, Shanghai, and Guangdong had large increases in exports, Anhui and Qinghai health products exports fell more. "Three-funded" and private enterprises are still the mainstay of the export of health products, and they together account for 89.56% of the total exports of health products.

Prospects for import and export in 2011 The Chinese government has always advocated Chinese medicine “going out of the country and going to the world”, and a large number of excellent companies such as Tong Ren Tang and Tasly have also emerged in the industry. They set up chain stores and image stores overseas and used a brand new marketing model. Bring Chinese herbal health products to all parts of the world. At the same time, we have also seen that the standards of various countries for the import of Chinese medicine products are gradually increasing, and some countries have introduced special laws and regulations. Therefore, if we want Chinese medicine to truly move toward the world, it is inevitable to increase industry concentration, achieve economies of scale, and strictly control quality. With the continuous advancement of new medical reforms in China and mergers and acquisitions among enterprises, we will expand and strengthen our products. Upgrading product quality and building a strong brand will be the theme of the development of the Chinese medicine industry in the future.

With the continuous increase in demand for green products in the international market, Chinese herbal product exports will continue to grow in 2011, and the dominant products will be mainly concentrated on plant extracts, Chinese herbal medicines, and health products. Foreign traders importing directly into the cultivation base of Chinese herbal medicines will also become increasingly standard and prevalent. This mode of reducing the purchase and sale of intermediate links will help increase labor costs and increase profitability. While the international market continues to maintain strong demand for Chinese herbal medicine products, we should also see that the introduction of the US cGMP ordinance, the implementation of the electronic database verification and management of the import of Korean herbal medicines, and the implementation of the European Union's “Regulations on Traditional Plant Drug Registration Procedures” are all The "examination paper" placed before Chinese medicine companies in China is an important issue that needs to be resolved in the Chinese medicine industry in 2011 and in the future.